Osimertinib

Osimertinib purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Jul 25:S1535-6108(25)00310-1. [Abstract]

Cells were treated for 72 h with the indicated concentrations of compounds (Osimertinib, etc.), and cell viability wasdetermined. Synergy scores (ZIP values) were calculated using the Zero Interaction Potency (ZIP)model in SynergyFinder (n = 3).

Osimertinib purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Jul 25:S1535-6108(25)00310-1. [Abstract]

Cells were treated for 72 h with the indicated concentrations of compounds (Osimertinib, etc.), and cell viability wasdetermined. Synergy scores (ZIP values) were calculated using the Zero Interaction Potency (ZIP)model in SynergyFinder (n = 3).

Osimertinib purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Jul 25:S1535-6108(25)00310-1. [Abstract]

Cells were treated for 72 h with the indicated concentrations of compounds (Osimertinib, etc.), and cell viability wasdetermined. Synergy scores (ZIP values) were calculated using the Zero Interaction Potency (ZIP)model in SynergyFinder (n = 3).

Osimertinib purchased from MedChemExpress. Usage Cited in: Science. 2026 Mar 26;391(6792):eadz9353. [Abstract]

Representative immunofluorescence images of PC9 cells stained for PI3 (green), FN1 (red), and nuclei [4′,6-diamidino-2-phenylindole (DAPI), blue] with or without 100 nM Osimertinib (4 days) treatment (scale bar, 50 μm).

Osimertinib purchased from MedChemExpress. Usage Cited in: Eur Heart J. 2025 Dec 3:ehaf813. [Abstract]

Osimertinib treatment (0.01–10 µM; 7 days) led to dose-dependent reduction in systolic (area under the curve, peak height, and departure velocity) measures in induced pluripotent stem cell-derived cardiomyocytes. n = 12 per group.

Osimertinib purchased from MedChemExpress. Usage Cited in: Eur Heart J. 2025 Dec 3:ehaf813. [Abstract]

There was a significant decrease in the protein level of MYLK3 following 7-day treatment of Osimertinib (1 µM). Additionally, MYL2 phosphorylation was also significantly reduced.

Osimertinib purchased from MedChemExpress. Usage Cited in: Eur Heart J. 2025 Dec 3:ehaf813. [Abstract]

Eight-week-old wild-type mice were subjected to transverse aortic constriction. After 1 week, Osimertinib (Osi, 25 mg/kg; oral gavage; once daily)-only treatment was conducted in Group 1, and Osimertinib and omecamtiv co-treatment was performed in Group 2. After another 2 weeks, omecamtiv treatment was initiated for the Osimertinib-only mice (Group 1). Echocardiography was conducted every week. Omecamtiv co-treatment effectively prevented left ventricular contractile dysfunction by Osimertinib in the course of 2 weeks, as revealed by an increase of ejection fraction and fractional shortening. When Osimertinib-treated mice with apparent cardiac dysfunction were introduced to omecamtiv co-treatment later, there was restoration of left ventricular contractile function.

Osimertinib purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Aug;37(32):e2504050. [Abstract]

The phosphorylation levels of EGFR-downstream substrates in H1975^OE cells treated without (Control) or with 500 nM AP-CRTAC^EGFR for 24 h, followed by 6 h of exposure to various concentrations of Osimertinib (Osi). The results showed that AP-CRTAC^EGFR effectively enhanced the efficacy of Osimertinib in inhibiting the phosphorylation of downstream signaling proteins.

Osimertinib purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Aug;37(32):e2504050. [Abstract]

Osimertinib (5 mg/kg; i.g.; once every two days for 14 days) monotherapy did not markedly inhibit tumor growth or reduce tumor weight in patient‑derived xenograft (PDX) mice, whereas combination treatment with AP-CRTAC^EGFR (80 nM/kg; i.t.; once every two days for 14 days) plus Osimertinib significantly suppressed tumor growth and decreased tumor weight.

Osimertinib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2023 Jun;4(6):829-843. [Abstract]

HCC827 and NCI-H2228 cancer cell lines were treated with 100 nM Osimertinib, 500 nM alectinib or 50 nM trametinib for 72 h as indicated. Immunofluorescence images of Scrib were merged with DAPI. Scale bar, 10 μm.

Osimertinib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2023 Jun;4(6):829-843. [Abstract]

Osimertinib-induced MRAS activation was abrogated by the addition of either SHP2 or SOS1 inhibitor in HCC827 cells. HCC827 cells were treated with 100 nM Osimertinib with or without 10 μM BI-3406 or 10 μM SHP099 for 72 h.

Osimertinib purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Feb 1;85(3):585-601. [Abstract]

T-cell–mediated tumor cell killing assay of LLC-Em cells. Cells were treated with or without anti–PD-L2 antibody, were given Osimertinib (1 μmol/L), selumetinib (1 μmol/L), and Osimertinib + selumetinib, respectively, and then cocultured with activated T cells for 72 hours. IFNγ secreted by CD8⁺ T cells was analyzed by flow cytometry.

Osimertinib purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Feb 1;85(3):585-601. [Abstract]

Tumor-bearing mice were treated with saline, Osimertinib (10 mg/kg), and ZU (100 mg/kg) intragastrically 5 times per week. Mouse anti-CD8 antibody was administered for four consecutive days on days 5 and 12 at 200 μg per mouse via i.p. injection. The models were divided into solvent groups, Osimertinib groups, small-molecule inhibitors ZU, and Osimertinib ZU combined administration groups, and ZU combined administration accompanied CD8⁺ T-cell depletion. Curves showing the tumor volumes from mice in the different groups (n = 6). The results showed that compared with the control treatment, combined Osimertinib and ZU administration significantly inhibited the growth of ectopic tumors, with the inhibition rate reaching 84.9%, but the antitumor effect of the combined treatment was obviously reduced when a CD8 blocking antibody was present.

Osimertinib purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 May 23;38(1):219. [Abstract]

U87 and U251 cells are exposed to indicated concentrations of AZD9291 (Osimertinib) for 24 h and then stimulated with EGF (100 ng/mL) for 30 min. Cell lysates are prepared and examined using Western blot analysis with indicated antibodies.

Osimertinib purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 May 23;38(1):219. [Abstract]

U87 and U251 cells are treated with AZD9291 (Osimertinib) or CP-358774 for 4, 24 and 48 h. The expression level of p-ERK are assessed using Western blot analysis.

Osimertinib purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 May 23;38(1):219. [Abstract]

GBM cells were treated by different concentrations of AZD9291 (Osimertinib) (0.625–20 μM) for 72 h. The cell viability was examined by CCK8 assay. Comparation of different sensitive of GBM cells to EGFR inhibitors (AZD9291, Erlotinib and Gefitinib).